NYSE:AGNAllergan Stock Price, Forecast & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 10 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allergan.

Allergan is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Allergan.

Allergan plc (NYSE:AGN) announced its quarterly earnings results on Monday, February, 10th. The company reported $5.22 earnings per share for the quarter, beating analysts' consensus estimates of $4.57 by $0.65. The business had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.09 billion. Allergan had a negative net margin of 15.44% and a positive return on equity of 8.46%. Allergan's revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the company posted $4.29 EPS. View Allergan's earnings history.

Allergan announced a quarterly dividend on Wednesday, March 18th. Stockholders of record on Thursday, April 16th will be paid a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 dividend on an annualized basis and a dividend yield of ∞. The ex-dividend date of this dividend is Wednesday, April 15th. View Allergan's dividend history.

Allergan declared that its board has approved a stock buyback plan on Tuesday, January 29th 2019, which allows the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 4.1% of its stock through open market purchases. Stock buyback plans are often a sign that the company's management believes its shares are undervalued.

10 equities research analysts have issued 12-month target prices for Allergan's shares. Their forecasts range from $165.00 to $203.00. On average, they expect Allergan's stock price to reach $184.89 in the next year. View analysts' price targets for Allergan.

Headlines about AGN stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Allergan earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Allergan.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan has a market capitalization of $0.00 and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe.

The official website for Allergan is www.allergan.com.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]